Recombinant Human SCD23 #abs01278

abs01278-5ug

1-2 Weeks

138

abs01278-20ug

1-2 Weeks

344

abs01278-1mg

1-2 Weeks

3891

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 was filtered through a 0.2 μm membrane and then lyophilized. By rearranging the original content, a highly similar one can be generated that conveys the same information.

Properties

aa_sequence

LMHWRDDNSE WVSQSHPERD QETSYWGDDG LFVRCGQKDC KPNFHRAYVT GISMCVSLFY QHEPGSQTSD SRDGSDLAHD TEGQMLCPVS GEQAHWDDPF VVLIWGPSGA SDNWVWYRDC PSMGCDSWQW QMEVAPGSLH RPSTSGDAPE HGPQERSLPR.It is important to note that the generated content may not reflect the original text accurately and should be used for reference purposes only.

Concentration

> 95 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The concentration of Recombinant Human CD23 was determined to be below 0.1 EU/μg using the LAL method. A highly similar content can be generated by rephrasing the information as follows:
According to the results obtained from the LAL method, the level of Recombinant Human CD23 was found to be less than 0.1 EU/μg.

Activity

The standard and ED were compared, and it was determined that the ED is fully biologically active. The content should be generated in a highly similar manner by rearranging the given information. The goal is to ensure that the generated content is based on the original text information, but not following the approach of generating dialogue as done using ChapGPT.₅₀The capacity of a substance to trigger the production of TNF-alpha by human PBMCs is what determines its effectiveness. The ability of this substance to induce the creation of TNF-alpha by human PBMCs serves as a measure of its potency and efficacy. Therefore, the performance of this substance is directly influenced by its capability to stimulate TNF-alpha production in the human PBMCs.

Reconstitution

To ensure the proper dispersion of the contents, we suggest giving the vial a brief spin in the centrifuge before opening. Prepare a solution by dissolving the contents in either sterile distilled water or an aqueous buffer with 0.1% BSA, aiming for a concentration of 0.1-1.0 mg/ml. It is advisable to divide the stock solutions into smaller working aliquots and store them at temperatures no higher than -20 °C. For further dilutions, use suitable buffered solutions.

Stability & Storage

This lyophilized preparation can be stored at 2-8 °C, but for long-term storage, it is recommended to keep it at -20 °C, preferably in a desiccated state. Upon reconstitution, the preparation remains stable for one week when stored at 2-8 °C. To ensure maximum stability, it is advisable to divide the reconstituted preparation into smaller working aliquots and store them at temperatures ranging from -20 °C to -70 °C. It is important to avoid subjecting the preparation to repeated freeze/thaw cycles.

Target

Accession

P06734

Gene IDs

2208